XML 25 R15.htm IDEA: XBRL DOCUMENT
v3.21.2

GOODWILL AND INTANGIBLE ASSETS | 9 Months Ended
--- | ---
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND INTANGIBLE ASSETS | GOODWILL AND INTANGIBLE ASSETS Goodwill The following table summarizes the changes in the carrying amount of goodwill:
(in millions) |  | Amount |
Balance at December 31, 2020 |  | $ | 8,108 |  |
Goodwill resulting from the acquisition of MYR |  | 226 |  |
Measurement period adjustments |  | (2) |  |
Balance at September 30, 2021 |  | $ | 8,332 |  |
Intangible Assets The following table summarizes our Intangible assets, net:
|  | September 30, 2021 |  | December 31, 2020
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (5,477) |  |  | $ | — |  |  | $ | 5,243 |  |  | $ | 10,720 |  |  | $ | (4,952) |  |  | $ | — |  |  | $ | 5,768 |
Intangible asset - axicabtagene ciloleucel(1) |  | 7,110 |  |  | (1,400) |  |  | — |  |  | 5,710 |  |  | 6,200 |  |  | (1,105) |  |  | — |  |  | 5,095 |
Intangible asset - Trodelvy(2) |  | 5,630 |  |  | (390) |  |  | — |  |  | 5,240 |  |  | 4,600 |  |  | (63) |  |  | — |  |  | 4,537 |
Intangible asset - Hepcludex |  | 845 |  |  | (50) |  |  | — |  |  | 795 |  |  | — |  |  | — |  |  | — |  |  | — |
Other |  | 1,410 |  |  | (619) |  |  | 1 |  |  | 792 |  |  | 1,377 |  |  | (540) |  |  | (1) |  |  | 836 |
Total finite-lived assets |  | 25,715 |  |  | (7,936) |  |  | 1 |  |  | 17,780 |  |  | 22,897 |  |  | (6,660) |  |  | (1) |  |  | 16,236 |
Indefinite-lived assets - IPR&D(1)(2)(3)(4) |  | 16,120 |  |  | — |  |  | — |  |  | 16,120 |  |  | 16,890 |  |  | — |  |  | — |  |  | 16,890 |
Total intangible assets |  | $ | 41,835 |  |  | $ | (7,936) |  |  | $ | 1 |  |  | $ | 33,900 |  |  | $ | 39,787 |  |  | $ | (6,660) |  |  | $ | (1) |  |  | $ | 33,126 |
_______________________________ (1) Gross carrying amount as of September 30, 2021 includes $910 million reclassified from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma. (2) Gross carrying amount as of September 30, 2021 includes Trodelvy for metastatic triple-negative breast cancer which was granted approval by FDA in April 2021 and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (“UC”) which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D. (3) Gross carrying amount as of September 30, 2021 includes $1.2 billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information. (4) In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million will be reclassified to finite-lived assets in the fourth quarter of 2021. Aggregate amortization expense related to finite-lived intangible assets was $441 million and $1.3 billion for the three and nine months ended September 30, 2021 and $281 million and $844 million for the three and nine months ended September 30, 2020, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations. The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September 30, 2021:
(in millions) |  | Amount
2021 (remaining three months) |  | $ | 441 |
2022 |  | 1,764 |
2023 |  | 1,764 |
2024 |  | 1,764 |
2025 |  | 1,759 |
Thereafter |  | 10,288 |
Total |  | $ | 17,780 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration